Skip to content
Clinic KLOW

Research digest · The numbers

KLOW peptide dosage: the research context, not a protocol

What the vial holds, which routes the components were studied by, and why the four can't be reduced to one number.

The studiesEffects & safety

The short version

First, the honest boundary: this page does not give human dosing for the KLOW peptide blend, and there is no validated human dose to give. With no controlled study of the blend and no regulated product, any "protocol" you see elsewhere is unverified.

What we can lay out is the research context. The canonical research vial is 80 mg total, split 50/10/10/10 across GHK-Cu, BPC-157, TB-500 and KPV. The four peptides were each studied on their own, by different routes and in different species, so their doses don't add up into a single "KLOW dose." And because the four clear from the body at very different speeds, one shared dose can't keep all of them at useful levels at the same time. We explain that mismatch below — as a fact about the chemistry, not a how-to.

KLOW dosage in the research context

There is no validated human dosing for the KLOW blend, and component-level research doses differ widely by species and route and are not additive into a single "KLOW dose." The only figure that is well-defined is the composition: a canonical 80 mg research vial of GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg, reconstituted with bacteriostatic water for laboratory handling.

Component doses in the studies show how different the four are. BPC-157 was given to rats as 10 micrograms, 10 nanograms or even 10 picograms per animal [2]; thymosin beta-4 stimulated keratinocyte migration at as little as 10 picograms in vitro [1]; KPV worked at 10 nM in cell culture and 100 micromolar in mouse drinking water [3]; GHK-Cu acts at low-nanomolar concentrations in cells and as topical formulations clinically [5]. None of these maps onto a human blend dose, and none should be read as guidance.

Promise Peptides product card for the KLOW blend, marked prescription only
Prescription accessPromise Peptides product card for KLOW (mypromise.com) — a compounded blend dispensed on a clinician's prescription, not a self-directed research purchase.

Where a dose actually comes from

A protocol is set by someone, and it is not this page

If none of the figures above maps onto a human blend dose, the obvious question is who decides one. In the research-chemical route, nobody does — the number is assembled by the person injecting it, from component studies in other species. Under prescription peptide therapy the number is set by a clinician against a chart: Promise Peptides (mypromise.com) is a licensed telehealth practice whose clinicians prescribe KLOW as a single compounded blend dispensed by a pharmacy. Naming that route is not a dose, and this page still has none to give — it is a statement about who is qualified to write one.

Why the four can't share one dose: the half-life mismatch

The peptides have markedly different reported half-lives, which is the core dosing problem with any single-vial blend. The formal PK study put BPC-157's elimination half-life under about 30 minutes, with linear kinetics, modest intramuscular bioavailability and rapid breakdown into normal amino-acid metabolism [18]. The tripeptides KPV and GHK-Cu — much smaller molecules — clear even faster. And the short TB-500 fragment behaves differently from full-length thymosin beta-4, whose Phase 1 pharmacokinetics were dose-proportional with half-life rising as dose rose [16].

Put those together and a single co-formulated dose cannot hold all four at matched exposures: by the time one arm is active, another may already be gone. This is a structural observation about the formulation, not a reason to dose any particular way.

Routes studied (in the component literature)

The component research covers several routes, and they differ by peptide. Subcutaneous injection is the common research-handling route for the blend. Beyond that, the literature covers topical delivery (GHK-Cu, with measured skin penetration and a dermal copper depot [19]), oral and targeted delivery (KPV via PepT1 [3]; BPC-157), and intra-articular injection (BPC-157, in the human knee-pain case series [6]).

Stability is worth a note: the blend is lyophilized and the reconstituted solution is typically refrigerated. Because GHK-Cu's copper(II) can participate in redox chemistry, co-dissolving it with three other peptides raises a theoretical compatibility consideration that has not been formally characterized for this mixture.

Where do you inject KLOW peptide?

This site does not provide human administration guidance. In the component research literature the routes studied include subcutaneous and intramuscular injection, with component-specific work also covering topical (GHK-Cu), oral or targeted delivery (KPV, BPC-157) and intra-articular (BPC-157) routes [6][19]. No validated human protocol exists for the blend.

How much KLOW peptide per day?

No validated human dose exists for the blend, and component research doses differ widely by species and route and are not additive into a single "KLOW dose" [2][3]. This site reports the research context only and does not provide human dosing.